(CercleFinance.com) – AstraZeneca announced Friday that the FDA has approved the use of its combination therapy Imfinzi and Imjudo in the treatment of stage 4 non-small cell lung cancer.
The biopharmaceutical group explains that the American health authority relied on clinical data showing that the combination of the two products, in addition to chemotherapy, reduced the risk of death by 23% compared to chemotherapy. only.
After two years of treatment, 33% of study participants were still alive, compared to 22% in the chemotherapy group.
Lung cancer remains the second most common cancer in the United States, with 236,000 diagnoses in 2021.
Only 8% of patients with metastatic non-small cell cancer are still alive five years after their diagnosis.
Imfinzi is a monoclonal antibody that helps counter tumor immune evasion tactics and promotes inhibition of the immune response.
Imjudo, another immunotherapy, blocks releases the brakes on T cell activation and stimulates the immune response against cancer cells.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
